Compare SIEB & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIEB | XBIT |
|---|---|---|
| Founded | 1886 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 74.4M |
| IPO Year | 1996 | 2015 |
| Metric | SIEB | XBIT |
|---|---|---|
| Price | $1.87 | $2.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 39.1K | 27.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $94,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.28 | N/A |
| 52 Week Low | $1.68 | $2.09 |
| 52 Week High | $5.46 | $3.61 |
| Indicator | SIEB | XBIT |
|---|---|---|
| Relative Strength Index (RSI) | 54.10 | 39.06 |
| Support Level | $1.88 | $2.26 |
| Resistance Level | $1.97 | $2.69 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 32.09 | 10.34 |
Siebert Financial Corp is a diversified financial services firm engaged in providing brokerage and financial advisory services. The coperates through two segments: Financial Services and Media, Sports and Entertainment. The Financial Services segment mainly operates as a securities broker-dealer and provides brokerage, custody, and clearing services for retail accounts, as well as insurance and advisory services, principal and proprietary trading, market making, securities lending, and investment banking and capital markets services. The Media, Sports and Entertainment segment is engaged in the production and distribution of music and media content, as well as talent management and sports representation. It generates the majority of its revenue from the Financial Services segment.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.